Discounted Cash Flow Rating

Buy

Return on Equity Rating

Neutral

Debt to Equity Rating

Strong Buy

Price to Earnings Rating

Sell

Analyst Rating

Buy

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Buy

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Neutral

Insider Trading

Neutral

Wall Street Data Solutions Rating

Buy

A

APi Group Corporation (APG)

Construction - Special Trade Contractors

https://www.apigroupinc.com

APi Group Corp operates in two operating segments, 1) Safety Services segment includes providing safety services in North America, Asia Pacific, and Europe, focusing on end-to-end integrated occupancy systems (fire protection solutions, Heating, Ventilation, and Air Conditioning and entry systems), including design, installation, inspection, and service of these integrated systems. These services are provided in commercial, education, healthcare, high tech, industrial, and special-hazard settings. 2) Specialty Services segment includes providing a variety of infrastructure services and specialized industrial plant services, which include maintenance and repair of critical infrastructure such as underground electric, gas, water, sewer, and telecommunications infrastructure.

C/O API GROUP, INC., 1100 OLD HIGHWAY 8 NW
NEW BRIGHTON, MN

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

10/05/2017

Market Cap

9,532,782,143

Shares Outstanding

243,860,000

Weighted SO

243,503,274

Total Employees

N/A

Upcoming Earnings

08/01/2024

Similar Tickers

BLD --.--%

MYRG --.--%

FIX --.--%

ROAD --.--%

PRIM --.--%

GVA --.--%

MTRX --.--%

ACA --.--%

EME --.--%

Beta

1.8200

Last Div

0.0000

Range

24.61-39.98

Chg

-0.2950

Avg Vol

2123795

Mkt Cap

9532782143

Exch

NYSE

Country

US

Phone

651 636 4320

DCF Diff

4.9193

DCF

29.3407

Div Yield

0.0000

P/S

1.3868

EV Multiple

17.2844

P/FV

3.2762

Div Yield %

0.0000

P/E

48.1248

PEG

6.6134

Payout

0.0000

Current Ratio

1.4765

Quick Ratio

1.3833

Cash Ratio

0.1949

DSO

96.7988

DIO

11.3741

Op Cycle

108.1730

DPO

31.1138

CCC

77.0592

Gross Margin

0.2764

Op Margin

0.0599

Pretax Margin

0.0394

Net Margin

0.0281

Eff Tax Rate

0.2878

ROA

0.0242

ROE

0.0754

ROCE

0.0654

NI/EBT

0.7122

EBT/EBIT

0.6578

EBIT/Rev

0.0599

Debt Ratio

0.3680

D/E

1.0335

LT Debt/Cap

0.5008

Total Debt/Cap

0.5082

Int Coverage

2.9640

CF/Debt

0.1904

Equity Multi

2.8081

Rec Turnover

3.7707

Pay Turnover

11.7311

Inv Turnover

32.0903

FA Turnover

10.8423

Asset Turnover

0.8635

OCF/Share

2.0549

FCF/Share

1.7456

Cash/Share

1.1932

OCF/Sales

0.0812

FCF/OCF

0.8495

CF Coverage

0.1904

ST Coverage

6.4884

CapEx Coverage

6.6429

Div&CapEx Cov

6.6429

P/BV

3.2762

P/B

3.2762

P/S

1.3868

P/E

48.1248

P/FCF

20.1114

P/OCF

16.6453

P/CF

16.6453

PEG

6.6134

P/S

1.3868

EV Multiple

17.2844

P/FV

3.2762

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Jun 15, 23:30 EHA 2025 | Multiple Studies Report Encouraging Data of Olverembatinib in Ph+ ALL GlobeNewswire Inc. Jun 09, 23:30 Thirteen Studies of Ascentage Pharma’s Assets Including Olverembatinib and Lisaftoclax Selected for Presentations at 2025 European Hematology Association Annual Congress GlobeNewswire Inc. Jun 02, 23:30 Live from ASCO 2025 | Ascentage Pharma Releases Promising Clinical Data on Alrizomadlin Monotherapy and Combinations in Solid Tumors GlobeNewswire Inc. Jun 02, 23:30 Live from ASCO 2025 | Ascentage Pharma Presents Clinical Data on Bcl-2 Inhibitor Lisaftoclax in Venetoclax-Refractory Patients in Oral Report GlobeNewswire Inc. May 23, 00:15 Ascentage Pharma Announces Clinical Data of Lisaftoclax, Which Shows Therapeutic Potential in Venetoclax-Refractory Patients, Selected for Oral Report at ASCO 2025 Investing.com Jul 06, 04:19 Insider Sale: Carl Dambkowski Sells Shares of Apogee Therapeutics Inc (APGE) By GuruFocus - Investing.com Canada Investing.com Jul 06, 02:57 Apogee Therapeutics CEO sells shares worth over $558k By Investing.com - Investing.com Australia Investing.com Jul 06, 02:56 Apogee Therapeutics CMO sells over $225k in company stock By Investing.com - Investing.com Australia GlobeNewswire Inc. Jan 02, 07:30 Apogee Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference MarketWatch Dec 28, 07:46 Here's a 'solid contrarian idea' for 2024, according to BTIG's Krinsky MarketWatch Dec 28, 06:34 Here's a 'solid contrarian idea' for 2024, according to BTIG's Krinsky GlobeNewswire Inc. Nov 13, 07:30 Apogee Highlights Corporate Progress and Reports Third Quarter 2023 Financial Results GlobeNewswire Inc. Nov 10, 18:22 Apollo Strategic Growth Capital II Will Redeem Its Public Shares and Will Not Consummate an Initial Business Combination GlobeNewswire Inc. Nov 10, 18:22 Apollo Strategic Growth Capital II Will Redeem Its Public Shares and Will Not Consummate an Initial Business Combination GlobeNewswire Inc. Nov 10, 18:22 Apollo Strategic Growth Capital II Will Redeem Its Public Shares and Will Not Consummate an Initial Business Combination GlobeNewswire Inc. Nov 10, 18:22 Apollo Strategic Growth Capital II Will Redeem Its Public Shares and Will Not Consummate an Initial Business Combination GlobeNewswire Inc. Nov 10, 18:22 Apollo Strategic Growth Capital II Will Redeem Its Public Shares and Will Not Consummate an Initial Business Combination GlobeNewswire Inc. Nov 10, 18:22 Apollo Strategic Growth Capital II Will Redeem Its Public Shares and Will Not Consummate an Initial Business Combination GlobeNewswire Inc. Nov 10, 18:22 Apollo Strategic Growth Capital II Will Redeem Its Public Shares and Will Not Consummate an Initial Business Combination GlobeNewswire Inc. Nov 10, 18:22 Apollo Strategic Growth Capital II Will Redeem Its Public Shares and Will Not Consummate an Initial Business Combination

Revenue Product Segmentation